Advertisement
Advertisement
ACH
A
Accendra Health, Inc.
1.96
USDSponsored
-0.07
-3.69%
Mar 20, 15:58 UTC -4
Closed
After-Market
1.94
-0.02
-0.77%
ACH Earnings Reports
Positive Surprise Ratio
ACH beat 1 of 2 last estimates.
50%
Next Report
Date of Next Report
May 06, 2026
Estimate for Q1 26 (Revenue/ EPS)
$652.82M
/-$0.10
Implied change from Q4 25 (Revenue/ EPS)
-7.92%
/-147.62%
Implied change from Q1 25 (Revenue/ EPS)
--
/-143.48%
Accendra Health, Inc. earnings per share and revenue
On Feb 19, 2026, ACH reported earnings of 0.21 USD per share (EPS) for Q4 25, missing the estimate of 0.22 USD, resulting in a -5.83% surprise. Revenue reached 708.97 million, compared to an expected 721.88 million, with a -1.79% difference. The market reacted with a +5.24% price change (close before vs. close after earnings).
Looking ahead to Q1 26, -- analysts forecast an EPS of -0.10 USD, with revenue projected to reach 652.82 million USD, implying an decrease of -147.62% EPS, and decrease of -7.92% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Capricor Therapeutics Inc
Report Date
Mar 12, 2026 For Q4 25
Estimate
-$0.55
Actual
-$0.62
Surprise
-12.56%
Kestra Medical Technologies, Ltd. Common Stock
Report Date
Mar 17, 2026 For Q3 26
Estimate
-$0.60
Actual
-$0.61
Surprise
-0.39%
Brainsway Ltd. - ADR
Report Date
Mar 11, 2026 For Q4 25
Estimate
$0.13
Actual
$0.26
Surprise
+98.02%
Sundial Growers Inc. Common Shares
Report Date
Mar 12, 2026 For Q4 25
Estimate
-$0.01
Actual
$0.04
Surprise
+499.62%
High Tide Inc. Common Shares
Report Date
Mar 17, 2026 For Q1 26
Estimate
$0.00
Actual
$0.01
Surprise
+447.68%
MacroGenics, Inc.
Report Date
Mar 09, 2026 For Q4 25
Estimate
-$0.29
Actual
-$0.23
Surprise
+22.40%
Apyx Medical Corporation Common Stock
Report Date
Mar 10, 2026 For Q4 25
Estimate
-$0.05
Actual
-$0.03
Surprise
+48.63%
Exagen Inc. Common Stock
Report Date
Mar 10, 2026 For Q4 25
Estimate
-$0.19
Actual
-$0.20
Surprise
-4.22%
Biote Corp. Class A Common Stock
Report Date
Mar 11, 2026 For Q4 25
Estimate
$0.05
Actual
$0.06
Surprise
+17.65%
Nephros Inc.
Report Date
Mar 12, 2026 For Q4 25
Estimate
$0.01
Actual
$0.08
Surprise
+684.31%
FAQ
What were Accendra Health, Inc.'s earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Accendra Health, Inc. reported EPS of $0.21, missing estimates by -5.83%, and revenue of $708.97M, -1.79% below expectations.
How did the market react to Accendra Health, Inc.'s Q4 2025 earnings?
The stock price moved up 5.24%, changed from $2.48 before the earnings release to $2.61 the day after.
When is Accendra Health, Inc. expected to report next?
The next earning report is scheduled for May 06, 2026.
What are the forecasts for Accendra Health, Inc.'s next earnings report?
Based on --
analysts, Accendra Health, Inc. is expected to report EPS of -$0.10 and revenue of $652.82M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement